Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases (1970–2003) on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and that in 14 drugs such genetic variation would require at least doubling of the dose in extensive metabolizers in comparison to poor metabolizers. Data for 38 antipsychotics were examined: for 13 of those CYP2D6 and CYP2C19 genotype was of relevance. To study the effects of genetic variability on pharmacodynamic pathways, we reviewed 80 clinical studies on polymorphisms in candidate genes, but those did not for the most part reveal significant associations between neurotransmitter receptor and transporter genotypes and therapy response or adverse drug reactions. In addition associations found in one study could not be replicated in other studies. For this reason, it is not yet possible to translate pharmacogenetic parameters fully into therapeutic recommendations. At present, antidepressant and antipsychotic drug responses can best be explained as the combinatorial outcome of complex systems that interact at multiple levels. In spite of these limitations, combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

[1]  S. Nanko,et al.  Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder , 1997, Molecular Psychiatry.

[2]  B. Lerer,et al.  Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility , 2000, Psychopharmacology.

[3]  M. Thase,et al.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors , 2001, British Journal of Psychiatry.

[4]  M. Nöthen,et al.  5HT 2a receptor T102C polymorphism and schizophrenia. , 1996, Lancet.

[5]  C. Alm,et al.  In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans , 1997 .

[6]  S. Tsai,et al.  Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. , 2000, Neuropsychobiology.

[7]  CYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations , 2000, Journal of clinical pharmacology.

[8]  U. Meyer,et al.  Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type , 2004, European Journal of Clinical Pharmacology.

[9]  R. Kaiser,et al.  Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia , 2002, Molecular Psychiatry.

[10]  S. Tsai,et al.  Serotonin-6 receptor variant (C267T) and clinical response to clozapine. , 1999, Neuroreport.

[11]  S. Tsai,et al.  Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response , 2003, Neuropsychopharmacology.

[12]  Tetsuo Shimizu,et al.  Association between -1438G/A Promoter Polymorphism in the 5-HT2A Receptor Gene and Fluvoxamine Response in Japanese Patients with Major Depressive Disorder , 2002, Neuropsychobiology.

[13]  L. Bertilsson,et al.  Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. , 1994, British journal of clinical pharmacology.

[14]  G. Reynolds,et al.  The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. , 2002, Journal of psychiatric research.

[15]  J. Sasse,et al.  Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. , 2003, Pharmacogenetics.

[16]  K. Brøsen,et al.  Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms , 1994, Clinical pharmacology and therapeutics.

[17]  Kyoko Suzuki,et al.  Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene , 2003, Psychiatric genetics.

[18]  R. Kerwin,et al.  No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response , 2000, Neuroscience Letters.

[19]  C. Cusin,et al.  Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. , 2002, The international journal of neuropsychopharmacology.

[20]  C J Timmer,et al.  Clinical Pharmacokinetics of Mirtazapine , 2000, Clinical pharmacokinetics.

[21]  G. Reynolds,et al.  Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. , 2003, The American journal of psychiatry.

[22]  C. Cusin,et al.  Tryptophan hydroxylase gene associated with paroxetine antidepressant activity , 2001, European Neuropsychopharmacology.

[23]  C. Bahr,et al.  Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype , 1991, Clinical pharmacology and therapeutics.

[24]  T. Shinkai,et al.  Polymorphisms of μ and δ opioid receptor genes and tardive dyskinesia in patients with schizophrenia , 2001, Schizophrenia Research.

[25]  G. Gervasini,et al.  Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine , 2003, Journal of clinical psychopharmacology.

[26]  J. Turgeon,et al.  The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin , 1996, Clinical pharmacology and therapeutics.

[27]  Kunihiko Ito,et al.  No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment , 2002, European Neuropsychopharmacology.

[28]  A. Serretti,et al.  Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. , 1999, The American journal of psychiatry.

[29]  D. Collier,et al.  Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. , 1995, American journal of medical genetics.

[30]  O. Wiborg,et al.  Steady‐state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism , 1996, Clinical pharmacology and therapeutics.

[31]  K. Midha,et al.  Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6 , 2004, European Journal of Clinical Pharmacology.

[32]  P. Fernández-Salguero,et al.  Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype , 2003, European Journal of Clinical Pharmacology.

[33]  T. Someya,et al.  The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population , 1999, Psychiatry and clinical neurosciences.

[34]  C. Benkelfat,et al.  Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia , 2000, Molecular Psychiatry.

[35]  G. Baker,et al.  Chirality and Drugs Used in Psychiatry: Nice to Know or Need to Know? , 1999, Cellular and Molecular Neurobiology.

[36]  S. Tsai,et al.  An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients , 2003, Neuroscience Letters.

[37]  I. Modai,et al.  Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. , 2002, American journal of medical genetics.

[38]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[39]  A. Malhotra,et al.  Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. , 1996, The American journal of psychiatry.

[40]  C. Cusin,et al.  SSRIs antidepressant activity is influenced by Gβ3 variants , 2003, European Neuropsychopharmacology.

[41]  H. Zhou,et al.  Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. , 2001, British journal of clinical pharmacology.

[42]  H. Sternbach The serotonin syndrome. , 1991, The American journal of psychiatry.

[43]  A. Caputi,et al.  Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects , 2004, European Journal of Clinical Pharmacology.

[44]  C. Eap,et al.  Plasma levels of the enantiomers of thioridazine, thioridazine 2‐sulfoxide, thioridazine 2‐sulfone, and thioridazine 5‐sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin , 1996, Clinical pharmacology and therapeutics.

[45]  D. Collier,et al.  Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine , 1996, Neuroscience Letters.

[46]  K. Itoh,et al.  Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[47]  Chul-Soo Park,et al.  Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics , 2002, Psychiatry and clinical neurosciences.

[48]  M. Thase New approaches to managing difficult-to-treat depressions. , 2003, The Journal of clinical psychiatry.

[49]  A. Malhotra,et al.  The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response , 1998, Molecular Psychiatry.

[50]  Paul J. Harrison,et al.  Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine , 2000, Psychopharmacology.

[51]  C. Eap,et al.  Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. , 2000, Therapeutic drug monitoring.

[52]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[53]  N. Yasui-Furukori,et al.  Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. , 2001, The American journal of psychiatry.

[54]  J. Mann,et al.  INCREASED SEROTONIN-2 BINDING SITES IN FRONTAL CORTEX OF SUICIDE VICTIMS , 1983, The Lancet.

[55]  M Schwab,et al.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.

[56]  K. Chiba,et al.  Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug , 1996, Psychopharmacology.

[57]  E. Tan,et al.  Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. , 2000, American journal of medical genetics.

[58]  J. Lieberman,et al.  Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia , 2001, Molecular Psychiatry.

[59]  D. Collier,et al.  Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine , 1998, Molecular Psychiatry.

[60]  S. Tsai,et al.  Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Molecular Psychiatry.

[61]  B. Gutiérrez,et al.  Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response , 2002, Schizophrenia Research.

[62]  L. Bertilsson,et al.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.

[63]  S. Tsai,et al.  Association between the Ser9Gly Polymorphism of the Dopamine D3 Receptor Gene and Tardive Dyskinesia in Chinese Schizophrenic Patients , 2001, Neuropsychobiology.

[64]  O. Spigset,et al.  Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors , 1997, Acta psychiatrica Scandinavica.

[65]  C. Halldin,et al.  A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone , 1995, Psychopharmacology.

[66]  C. Cusin,et al.  No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors , 2001, Psychiatry Research.

[67]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.

[68]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[69]  M. Cronin,et al.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.

[70]  K. Chiba,et al.  Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. , 1996, Journal of clinical psychopharmacology.

[71]  G. Reynolds,et al.  Association of a polymorphism in the promoter region of theserotonin 5-HT2Creceptor gene with tardive dyskinesia in patients with schizophrenia , 2002, Molecular Psychiatry.

[72]  Ö. Ericsson,et al.  Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype , 1987, Clinical pharmacology and therapeutics.

[73]  L. Bertilsson,et al.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.

[74]  S. Cichon,et al.  Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. , 1994, Human molecular genetics.

[75]  E. Ford,et al.  Genetic polymorphism , 2020, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[76]  H. Möller,et al.  Efficacy and Side-Effects of Clozapine: Testing for Association with Allelic Variation in the Dopamine D4 Receptor Gene , 1996, Neuropsychopharmacology.

[77]  L. Bertilsson,et al.  The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. , 1997, Journal of clinical psychopharmacology.

[78]  J. Sasse,et al.  Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. , 2003, Pharmacogenetics.

[79]  J. Turgeon,et al.  Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. , 1999, Pharmacogenetics.

[80]  B. Lerer,et al.  Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia , 2002, Biological Psychiatry.

[81]  Alan A. Wilson,et al.  The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. , 2001, The American journal of psychiatry.

[82]  T. Iga,et al.  Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9‐Hydroxyrisperidone in Japanese Patients with Schizophrenia , 2003, Journal of clinical pharmacology.

[83]  H. Klein,et al.  Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. , 2000, American journal of medical genetics.

[84]  Alex J Sutton,et al.  Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. , 2002, International journal of epidemiology.

[85]  Ai-Ming Yu,et al.  Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. , 2003, Pharmacogenetics.

[86]  P. Zwanzger,et al.  Combined action of the ACE D- and the G-protein β3 T-allele in major depression: a possible link to cardiovascular disease? , 2002, Molecular Psychiatry.

[87]  P. Zwanzger,et al.  Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on theraputic outcome in affective disorders , 2001, Molecular Psychiatry.

[88]  E. Tan,et al.  Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[89]  B. Pollock,et al.  Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. , 1995, Psychopharmacology bulletin.

[90]  K. Hornik,et al.  Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients , 1999, European Neuropsychopharmacology.

[91]  S. Tsai,et al.  Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia , 2001, Psychiatric genetics.

[92]  Ya-Mei Bai,et al.  Association Study of the Estrogen Receptor Polymorphisms with Tardive Dyskinesia in Schizophrenia , 2003, Neuropsychobiology.

[93]  S. Tsai,et al.  Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment , 2002, Psychiatric genetics.

[94]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[95]  R. Ebstein,et al.  Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects , 1997, European Neuropsychopharmacology.

[96]  Paul J. Harrison,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Genes for Schizophrenia? Recent Findings and Their Pathophysiological Implications , 2022 .

[97]  D. Collier,et al.  Dopamine D4 receptor subtypes and response to clozapine , 1993, The Lancet.

[98]  H. Seyberth,et al.  Pathogenetic role of cyclooxygenase‐2 in hyperprostaglandin E syndrome/antenatal bartter syndrome: Therapeutic use of the cyclooxygenase‐2 inhibitor nimesulide , 2001, Clinical pharmacology and therapeutics.

[99]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[100]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[101]  J. Turgeon,et al.  Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. , 2003, Pharmacogenetics.

[102]  C. Alm,et al.  Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism , 1994, Clinical pharmacology and therapeutics.

[103]  C. Eap,et al.  Enantiomeric antidepressant drugs should be considered on individual merit , 2001, Human psychopharmacology.

[104]  E. Seifritz,et al.  Antidepressive Response to Sleep Deprivation in Unipolar Depression Is Not Associated with Dopamine D3 Receptor Genotype , 2001, Neuropsychobiology.

[105]  H. Manji,et al.  Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression , 2003, Biological Psychiatry.

[106]  E. Gershon,et al.  Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. , 1994, Archives of general psychiatry.

[107]  R. Barbhaiya,et al.  Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. , 1996, British journal of clinical pharmacology.

[108]  W. Tang,et al.  Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients , 2001, Journal of Neural Transmission.

[109]  R. Zhu,et al.  The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects , 2002, European Journal of Clinical Pharmacology.

[110]  E. Tan,et al.  Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor , 2001, Biological Psychiatry.

[111]  B. Cohen,et al.  Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs , 1999, Psychopharmacology.

[112]  H. Möller,et al.  Genetic variation of the 5-HT2A receptor and response to clozapine. , 1995, Lancet.

[113]  A. Malhotra,et al.  Clozapine response and the 5HT2C Cys23Ser polymorphism , 1996, Neuroreport.

[114]  H. Shibuya,et al.  Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[115]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[116]  L. Balant,et al.  Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man , 2005, Archiv für Psychiatrie und Nervenkrankheiten.

[117]  T. Someya,et al.  Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. , 2000, Pharmacology & toxicology.

[118]  M. S. Ching,et al.  Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. , 2000, Pharmacogenetics.

[119]  J. Hauser,et al.  Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects , 2001, Molecular Psychiatry.

[120]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[121]  Ying-Chieh Wang,et al.  Association analysis of polymorphism in the promoter region of the α2a-adrenoceptor gene with schizophrenia and clozapine response , 2001, Schizophrenia Research.

[122]  T. Someya,et al.  Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. , 2000, Journal of clinical psychopharmacology.

[123]  L. Bertilsson,et al.  The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol , 1996, Clinical pharmacology and therapeutics.

[124]  L. Bertilsson,et al.  Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation , 1983, Clinical pharmacology and therapeutics.

[125]  V. Steen,et al.  Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. , 2000, The international journal of neuropsychopharmacology.

[126]  Zhaoqian Liu,et al.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[127]  C. Gleiter,et al.  Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. , 1994, British journal of clinical pharmacology.

[128]  B. Lerer,et al.  Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia , 2001, Molecular Psychiatry.

[129]  Jun Yu Li,et al.  Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome , 2002, Biological Psychiatry.

[130]  M. Dahl,et al.  Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. , 1995, Journal of clinical psychopharmacology.

[131]  Michael Gill,et al.  No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families , 1998, Psychiatry Research.

[132]  S. Reddy,et al.  Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers , 2003, Clinical pharmacology and therapeutics.

[133]  P. Zwanzger,et al.  Evidence for an association between a G-protein-β3-gene variant with depression and response to antidepressant treatment , 2000, European Neuropsychopharmacology.

[134]  O. Spigset,et al.  Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes , 2001, European Journal of Clinical Pharmacology.

[135]  O. Olesen,et al.  Serum concentrations and side effects in psychiatric patients during risperidone therapy. , 1998, Therapeutic drug monitoring.

[136]  Yuhei Nakamura,et al.  Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia , 1998, Psychiatry Research.

[137]  E. Steiner,et al.  Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators , 1987, Clinical pharmacology and therapeutics.

[138]  J. Hauser,et al.  Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene , 2002, Psychiatry Research.

[139]  T. Shinkai,et al.  Genetic association analysis of 5-HT6 receptor gene polymorphism (267C/T) with tardive dyskinesia , 2002, Psychiatry Research.

[140]  L. Bertilsson,et al.  CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients , 2000, European Journal of Clinical Pharmacology.

[141]  L. Bertilsson,et al.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype , 1996, Psychopharmacology.

[142]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[143]  S. Tsai,et al.  Genetic variants of the serotonin system and weight change during clozapine treatment. , 2001, Pharmacogenetics.

[144]  O. Andreassen,et al.  Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients , 1997, Psychopharmacology.

[145]  P. Baumann,et al.  N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients , 1985 .

[146]  P. Sokoloff,et al.  Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene , 1993, Acta psychiatrica Scandinavica.

[147]  P. Bech,et al.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism , 2004, European Journal of Clinical Pharmacology.

[148]  D. Hamer,et al.  A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.

[149]  S. Tsai,et al.  Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[150]  M. Rietschel,et al.  Pharmacogenetics of clozapine response , 2000, The Lancet.

[151]  K. Brøsen,et al.  The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. , 1999, Pharmacogenetics.

[152]  P. Haffmans,et al.  Venlafaxine serum levels and CYP2D6 genotype. , 2000, Therapeutic drug monitoring.

[153]  M. Rietschel,et al.  Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. , 2001, American journal of medical genetics.

[154]  E. Sellers,et al.  Venlafaxine oxidation in vitro is catalysed by CYP2D6. , 1996, British journal of clinical pharmacology.

[155]  J. Lieberman,et al.  Lack of association between the T→C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia , 2001, Schizophrenia Research.

[156]  S. Kasper,et al.  CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages , 2001, Acta psychiatrica Scandinavica.

[157]  K. Brøsen,et al.  Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms , 1993, Therapeutic drug monitoring.

[158]  R. Ganguli,et al.  5‐HT2 receptor gene locus: association with schizophrenia or treatment response not detected , 1996, Psychiatric genetics.

[159]  D. Collier,et al.  Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. , 1998, Pharmacogenetics.

[160]  M. Okawa,et al.  Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position −2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[161]  M. Thase,et al.  Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. , 2001, The Journal of clinical psychiatry.

[162]  H. Möller,et al.  Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. , 1995, International journal of clinical pharmacology and therapeutics.

[163]  M. Thase Overview of antidepressant therapy. , 2001, Managed care.

[164]  M. Fava,et al.  Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment , 2003, Biological Psychiatry.

[165]  J. Hallas,et al.  The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine , 1991, Clinical pharmacology and therapeutics.

[166]  T. Someya,et al.  Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. , 1999, Therapeutic drug monitoring.

[167]  Ann Daly,et al.  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.

[168]  W. Potter,et al.  Metabolism of Tricyclic Antidepressants , 1999, Cellular and Molecular Neurobiology.

[169]  J. Azuma,et al.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. , 1999, British journal of clinical pharmacology.

[170]  E. Mundo,et al.  The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. , 2001, Archives of general psychiatry.

[171]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[172]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[173]  M. Okawa,et al.  The Impact of CYP2C19 and CYP2D6 Genotypes on Metabolism of Amitriptyline in Japanese Psychiatric Patients , 2002, Journal of clinical psychopharmacology.

[174]  J. Brockmöller,et al.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[175]  F. Macciardi,et al.  Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. , 1998, Therapeutic drug monitoring.

[176]  R. Roos,et al.  Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. , 2002, Pharmacogenetics.

[177]  I. Kanazawa,et al.  Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. , 1993, Pharmacogenetics.

[178]  M. Ingelman-Sundberg,et al.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. , 2003, British journal of clinical pharmacology.

[179]  J. Brockmöller,et al.  The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment , 2002, Clinical pharmacology and therapeutics.

[180]  K. Brøsen,et al.  Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[181]  M. Nöthen,et al.  5HT2a receptor T102C polymorphism and schizophrenia , 1996, The Lancet.

[182]  M. J. Arranz,et al.  Association between clozapine response and allelic variation in 5-HT2A receptor gene , 1995, The Lancet.

[183]  M. Ingelman-Sundberg,et al.  PCR-based genotyping for duplicated and deleted CYP2D6 genes. , 1996, Pharmacogenetics.

[184]  T. Shinkai,et al.  Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia , 2000, Neuropsychopharmacology.

[185]  S. Tsai,et al.  Association Analysis for Neuronal Nitric Oxide Synthase Gene Polymorphism with Major Depression and Fluoxetine Response , 2003, Neuropsychobiology.

[186]  J. Daléry,et al.  Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes , 1999, European Journal of Clinical Pharmacology.

[187]  A. Peer,et al.  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects , 1993, Clinical pharmacology and therapeutics.

[188]  K. Brøsen,et al.  Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6 , 2001, European Journal of Clinical Pharmacology.

[189]  D. Nutt,et al.  Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death , 2003, Journal of clinical psychopharmacology.

[190]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[191]  N. Yasui-Furukori,et al.  Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[192]  C. Cusin,et al.  Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression , 2001, Biological Psychiatry.

[193]  D. Kupfer,et al.  Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.

[194]  O. Spigset,et al.  Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms , 1997, European Journal of Clinical Pharmacology.

[195]  P. Tu,et al.  No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. , 1999, Neuroreport.

[196]  K. Brøsen,et al.  Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism , 2005, European Journal of Clinical Pharmacology.

[197]  T Ishizaki,et al.  High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. , 1999, Pharmacogenetics.

[198]  H. Möller,et al.  Beta‐1‐adrenergic receptor gene in major depression: Influence on antidepressant treatment response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[199]  T. Marandi,et al.  Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype , 2002, Psychopharmacology.

[200]  É. Zarifian,et al.  Substantial rise in sparteine metabolic ratio during haloperidol treatment. , 1989, British journal of clinical pharmacology.

[201]  Bradford Ld CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[202]  David Curtis,et al.  Association between clozapine response and allelic variation in the 5-HT2C receptor gene , 1995, Neuroreport.

[203]  T. Hanihara,et al.  Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. , 1998, The American journal of psychiatry.

[204]  J. Fourie,et al.  Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine , 2001, Journal of clinical psychopharmacology.

[205]  G. Reynolds,et al.  Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism , 2002, The Lancet.

[206]  P. Zwanzger,et al.  Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression , 2001, Neuroscience Letters.

[207]  C. Alm,et al.  Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.

[208]  L. Ereshefsky,et al.  CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. , 1999, Journal of clinical psychopharmacology.

[209]  K. Otani,et al.  Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. , 1997, Pharmacogenetics.

[210]  C. Cusin,et al.  Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity , 2001, Molecular Psychiatry.

[211]  M. Thase Effectiveness of antidepressants: comparative remission rates. , 2003, The Journal of clinical psychiatry.

[212]  S. Tsai,et al.  Association Study of the 5-HT6 Receptor Polymorphism (C267T) and Symptomatology and Antidepressant Response in Major Depressive Disorders , 2001, Neuropsychobiology.

[213]  Jeffrey A Lieberman,et al.  Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients , 1998, Neuropsychopharmacology.

[214]  Michael Bader,et al.  Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform , 2003, Science.

[215]  Michael Grözinger,et al.  Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. , 2003, Pharmacopsychiatry.

[216]  I. Poggesi,et al.  Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor , 1997, European Neuropsychopharmacology.

[217]  C Reist,et al.  Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. , 2001, American journal of medical genetics.

[218]  E. Smeraldi,et al.  Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. , 2000, Journal of clinical psychopharmacology.

[219]  K. Chiba,et al.  Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy , 1997, Psychiatry and clinical neurosciences.

[220]  J. Scharfetter Dopamine receptor polymorphisms and drug response in schizophrenia. , 2001, Pharmacogenomics.

[221]  H. Meltzer Action of atypical antipsychotics. , 2002, The American journal of psychiatry.

[222]  D. Flockhart,et al.  Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) , 1999, Clinical pharmacology and therapeutics.

[223]  S. Tsai,et al.  Association study of Angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Journal of Neural Transmission.

[224]  L. Bertilsson,et al.  Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers , 1986, Clinical pharmacology and therapeutics.

[225]  Fabio Macciardi,et al.  Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism , 2002, Neuropsychopharmacology.

[226]  T. Shinkai,et al.  Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. , 2001, American journal of medical genetics.

[227]  S. Caccia New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. , 2002, Current opinion in investigational drugs.

[228]  M. Egan,et al.  The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.

[229]  K. Itoh,et al.  A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine , 2002, Psychiatry Research.

[230]  S. Loft,et al.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine , 1996, European Journal of Clinical Pharmacology.

[231]  K. Hsiao,et al.  Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia , 1997, Biological Psychiatry.

[232]  C. Sánchez,et al.  Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding , 1999, Cellular and Molecular Neurobiology.

[233]  K. Brøsen,et al.  Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study * , 1995, Clinical pharmacology and therapeutics.

[234]  B Müller-Oerlinghausen,et al.  Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia , 2001, Molecular Psychiatry.

[235]  S. Caccia Metabolism of the Newer Antidepressants , 1998, Clinical pharmacokinetics.

[236]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[237]  L. Bertilsson,et al.  Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test , 2001, Clinical pharmacology and therapeutics.

[238]  H. Möller,et al.  Efficacy and side‐effects of clozapine not associated with variation in the 5‐HT2C receptor , 1997, Neuroreport.

[239]  J. Wu,et al.  D2 dopamine receptor polymorphism and brain regional glucose metabolism. , 1997, American journal of medical genetics.

[240]  D. Collier,et al.  Association analysis of the 5‐HT5A gene in depression, psychosis and antipsychotic response , 2000, Neuroreport.

[241]  C. Hiemke,et al.  The role of cytochrome P450 2D6 in the metabolism of moclobemide , 1996, European Neuropsychopharmacology.

[242]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[243]  B. Lerer,et al.  Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia , 1999, Molecular Psychiatry.

[244]  T. Lehtimäki,et al.  Catechol-O-methyltransferase and Monoamine Oxidase A Genotypes and Drug Response to Conventional Neuroleptics in Schizophrenia , 2003, Journal of clinical psychopharmacology.

[245]  A. Schatzberg,et al.  Pharmacogenetics of antidepressant medication intolerance. , 2003, The American journal of psychiatry.

[246]  W. Siffert,et al.  Interaction of the ACE D Allele and the GNB3 825T Allele in Myocardial Infarction , 2000, Hypertension.

[247]  J. Brockmöller,et al.  Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. , 2002, Pharmacogenetics.

[248]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[249]  S. Caccia Biotransformation of post-clozapine antipsychotics: pharmacological implications. , 2000, Clinical pharmacokinetics.

[250]  L. Bertilsson,et al.  Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. , 1992, Therapeutic drug monitoring.

[251]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[252]  C. Eap,et al.  Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers , 2001, Journal of clinical psychopharmacology.

[253]  M. Jann,et al.  Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype , 2002, Drug Metabolism and Drug Interactions.

[254]  K. Otani,et al.  Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia , 1999, Clinical pharmacology and therapeutics.

[255]  S. Tsai,et al.  Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response 1 1 The experiments in this study were performed at the Molecular Biology Laboratory, Department of Psychiatry, Veterans General Hospital Taipei, Taipei, Taiwan , 2000, Schizophrenia Research.

[256]  S. Tsai,et al.  −759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain , 2002, The Lancet.

[257]  L. Bertilsson,et al.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. , 2001, British journal of clinical pharmacology.

[258]  M. Dahl Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics , 2002, Clinical pharmacokinetics.

[259]  B. Pollock,et al.  Bupropion plasma levels and CYP2D6 phenotype. , 1996, Therapeutic drug monitoring.

[260]  R. Fukuda,et al.  C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses , 1998, Molecular Psychiatry.

[261]  M Masellis,et al.  D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine , 2003, Molecular Psychiatry.

[262]  L. Bertilsson,et al.  Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients , 2001, European Journal of Clinical Pharmacology.

[263]  R. Ebstein,et al.  Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. , 1997, Human heredity.

[264]  R. Blouin,et al.  Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine , 1990, Acta psychiatrica Scandinavica. Supplementum.

[265]  A. Caputi,et al.  Debrisoquine oxidation phenotype and neuroleptic‐induced dystonic reactions , 1992, Acta psychiatrica Scandinavica.

[266]  L. Bertilsson,et al.  Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) , 2002, Clinical pharmacology and therapeutics.

[267]  J. Quinn,et al.  A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[268]  J. Idle,et al.  Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype , 1997, British Journal of Psychiatry.

[269]  M. Rietschel,et al.  Dopamine D3 receptor variant and tardive dyskinesia , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[270]  R. Kaiser,et al.  Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia , 2000, Molecular Psychiatry.

[271]  L. Bertilsson,et al.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.

[272]  C. Alm,et al.  Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings , 1989, Clinical pharmacology and therapeutics.

[273]  H. V. Van Tol,et al.  Polymorphisms in dopamine receptors: what do they tell us? , 2000, European journal of pharmacology.

[274]  L. Bertilsson,et al.  Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes , 1998, Clinical pharmacology and therapeutics.

[275]  A. Serretti,et al.  Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation , 1999, Psychiatry Research.

[276]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[277]  R. Kim,et al.  Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. , 1999, Pharmacogenetics.

[278]  O. Spigset,et al.  Non-linear fluvoxamine disposition. , 1998, British journal of clinical pharmacology.

[279]  J. Barrett,et al.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. , 2003, British journal of clinical pharmacology.

[280]  G. Reynolds,et al.  Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia , 2003, Psychiatric genetics.

[281]  S. Tsuchida,et al.  Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine , 1997, Psychopharmacology.

[282]  D. Collier,et al.  Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia , 1996, Human Genetics.

[283]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[284]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. , 1996, The Journal of pharmacology and experimental therapeutics.

[285]  L. Ereshefsky,et al.  CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady‐State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6 , 2002, Pharmacotherapy.

[286]  A. Molven,et al.  Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? , 2001, Pharmacogenetics.

[287]  Slobodan Petar Rendic Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[288]  L. Bertilsson,et al.  Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans , 1991, Acta psychiatrica Scandinavica.

[289]  V. Steen,et al.  Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients , 1997, Molecular Psychiatry.

[290]  M. Jann,et al.  Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients , 1997, Psychiatry Research.

[291]  D. Sibley,et al.  Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. , 1999, Pharmacogenetics.

[292]  Fabio Macciardi,et al.  Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia , 1999, Neuropsychopharmacology.

[293]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[294]  C. Cusin,et al.  SSRIs antidepressant activity is influenced by G beta 3 variants. , 2003, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[295]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[296]  O. Wiborg,et al.  Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. , 1996, Therapeutic drug monitoring.

[297]  P. Sokoloff,et al.  Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia , 2000, Molecular Psychiatry.

[298]  H. Möller,et al.  Association analysis of a polymorphism in the G-protein stimulatory alpha subunit in patients with major depression. , 2002, American journal of medical genetics.

[299]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[300]  S. Tsai,et al.  Association Study of Apolipoprotein Eε4with Clinical Phenotype and Clozapine Response in Schizophrenia , 2000, Neuropsychobiology.

[301]  J. Hauser,et al.  A Polymorphism of the Norepinephrine Transporter Gene in Bipolar Disorder and Schizophrenia: Lack of Association , 2002, Neuropsychobiology.

[302]  K. Wernecke,et al.  Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics , 2003, Journal of clinical psychopharmacology.

[303]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[304]  K. Itoh,et al.  Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[305]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[306]  R. Kerwin,et al.  Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response , 2002, Neuroscience Letters.

[307]  P. Baumann,et al.  Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. , 1986, International clinical psychopharmacology.

[308]  S. Otton,et al.  Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype , 1986, Clinical pharmacology and therapeutics.

[309]  M. Okawa,et al.  The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients , 2001, Journal of clinical psychopharmacology.